2025-09-09 - Analysis Report
Okay, here's a report summarizing the provided information on Intuitive Surgical (ISRG), along with an analysis.

## ISRG (Intuitive Surgical Inc.) Stock Analysis

**Company Overview:** Intuitive Surgical is a global technology leader in robotic-assisted surgery.

### 1. Performance vs. S&P 500 (VOO)

*   **ISRG Cumulative Return:** 101.72%
*   **VOO Cumulative Return:** 101.31%
*   **Absolute Divergence (Current):** 0.4%
*   **Divergence Range:** Max: 127.7, Min: -6.8
*   **Relative Divergence:** 5.4

**Analysis:** ISRG has slightly outperformed the S&P 500 in cumulative return by 0.4%. However, the relative divergence of 5.4 indicates that ISRG's performance, relative to VOO, is near the lower end of its historical range.

**Alpha, Beta Analysis:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 68.0% | 56.5% | 39.0% | 0.0 | 43.9 |
| 2016-2018  | 77.0% | 63.4% | 59.0% | 0.0 | 57.6 |
| 2017-2019  | 81.0% | 63.4% | 52.0% | 0.3 | 71.1 |
| 2018-2020  | 47.0% | 63.4% | 28.0% | 0.2 | 98.4 |
| 2019-2021  | 91.0% | 63.0% | 43.0% | 0.2 | 129.7 |
| 2020-2022  | -3.0% | 69.9% | -6.0% | 0.2 | 95.8 |
| 2021-2023  | -5.0% | 72.9% | -23.0% | 0.9 | 121.8 |
| 2022-2024  | 26.0% | 72.9% | 0.0% | 0.9 | 188.4 |
| 2023-2025  | 22.0% | 72.9% | -31.0% | 0.7 | 168.5 |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate (CAGR) demonstrates high growth in earlier periods (2015-2021), with a significant slowdown and negative growth in later periods (2020-2023), followed by a recovery in recent years.
*   **MDD:** The Maximum Drawdown (MDD) indicates substantial risk, especially in recent periods, reflecting significant price volatility.
*   **Alpha:** The Alpha values show periods of outperformance (positive Alpha) and underperformance (negative Alpha) relative to the market. Recent years show significant underperformance.
*   **Beta:** The Beta values indicate the stock's volatility compared to the market. The Beta values close to 0 in early periods suggest the stock was less volatile. Recent increases in Beta suggest higher volatility.
*   **Cap(B):** The Market Capitalization (Cap(B)) has generally increased, reflecting growth in the company's size, despite recent performance challenges.

### 2. Recent Stock Price Movements

*   **Current Price:** 466.86
*   **Last Market Price:** 470.0 (Change: 0.67 from previous close of 466.86)
*   **5-Day Moving Average:** 456.996
*   **20-Day Moving Average:** 470.9725
*   **60-Day Moving Average:** 498.1477

**Analysis:** The current price is below the 20-day and 60-day moving averages, suggesting a short-term downtrend. The price is slightly above the 5-day moving average, indicating a potential short-term rebound.  The recent market price data indicates a slight increase (change of 0.67), possibly indicating a minor upward momentum.

### 3. Market Risk Indicators and Expected Return

*   **Market Risk Indicator (MRI):** 0.33 (Low Risk)
*   **RSI:** 43.22
*   **PPO:** -0.0997
*   **Hybrid Signal:** cash_69%_Sell 69.4% of holdings (396 shares - Caution - MRI:0.33) (Cash Ratio: 69% on 2025-09-04)
*   **Delta_Previous_Relative_Divergence (20-day):** -5.2 (Negative - Short-term decrease)
*   **Expected Return:** 778.9%

**Analysis:**

*   The **MRI** suggests a low-risk environment, but the hybrid signal indicates a cautious approach with a recommendation to sell a significant portion of holdings and increase the cash ratio.
*   The **RSI** of 43.22 is approaching oversold territory but is not yet at a level that would definitively signal a buy.
*   The **PPO** is negative, indicating that the short-term moving average is below the long-term moving average, reinforcing the downtrend signal.
*   A negative **Delta_Previous_Relative_Divergence** suggests a short-term decline relative to the benchmark.
*   The **Expected Return** is extraordinarily high, implying significant potential upside over the long term (2+ years) compared to the S&P 500, but must be viewed with caution due to the recent negative performance.
*   The fact that **price** has risen a small amount (0.67) from **previousClose** could signal a minor upward trend.

### 4. Recent News & Significant Events

*   **[2025-09-07]** 2 Beaten-Down Stocks to Buy on the Dip (Motley Fool)
*   **[2025-09-05]** Medtronic trial of Hugo robot in hernia repair hits primary endpoints (MedTech Dive) - Competitor news.
*   **[2025-09-05]** Intuitive Surgical Stock Has Been Plummeting. Is It Time to Buy? (Motley Fool)
*   **[2025-09-04]** Ashes to Alpha: Why Intuitive Surgical’s (ISRG) Fallout is a Legit Upside Opportunity (Barchart)
*   **[2025-09-04]** 1 Cash-Producing Stock to Consider Right Now and 2 That Underwhelm (StockStory)
*   **[2025-09-03]** S&P 500 Robotics Titan Intuitive Surgical Dives As CFO Warns Of 'Dynamic' Tariffs Environment (Investor's Business Daily)

**Analysis:** The news is mixed. Some articles suggest a potential buying opportunity due to recent price declines ("beaten-down stock," "fallout is a legit upside opportunity"). However, concerns are raised about "plummeting" stock and CFO warnings about "dynamic" tariffs.  The Medtronic news suggests increasing competition in the robotic surgery space.

### 4-2) Analyst Opinions

*   **Consensus:** Buy (Mean: 1.94)
*   **Target Price:** Avg: 582.10 / High: 685.00 / Low: 350.00

**Analysis:**  Analysts generally have a "Buy" rating and a significant upside target price compared to the current price. However, the wide range of target prices suggests some uncertainty. The lack of information about recent rating changes makes it difficult to gauge the current analyst sentiment fully.

### 5. Recent Earnings Analysis

| 날짜       | EPS  | 매출    |
|------------|------|---------|
| 2025-07-23 | 1.84 | 2.44 B$ |
| 2025-04-23 | 1.95 | 2.25 B$ |
| 2024-10-18 | 1.59 | 2.04 B$ |
| 2024-07-19 | 1.48 | 2.01 B$ |
| 2025-07-23 | 1.48 | 2.01 B$ |

**Analysis:** The earnings data shows a generally upward trend in both EPS (Earnings Per Share) and revenue, with a slight dip in one period (2025-07-23), which is concerning and may reflect a recent slowdown in growth or increased costs.

### 6. Financial Information

| Quarter      | Revenue | Profit Margin |
|--------------|---------|---------------|
| 2025-06-30   | $2.44B  | 66.31%        |
| 2025-03-31   | $2.25B  | 64.69%        |
| 2024-12-31   | $2.41B  | 68.04%        |
| 2024-09-30   | $2.04B  | 67.41%        |
| 2024-06-30   | $2.01B  | 68.30%        |

| Quarter      | Equity    | ROE     |
|--------------|-----------|---------|
| 2025-06-30   | $17.85B   | 3.69%   |
| 2025-03-31   | $17.11B   | 4.08%   |
| 2024-12-31   | $16.43B   | 4.17%   |
| 2024-09-30   | $15.58B   | 3.63%   |
| 2024-06-30   | $14.71B   | 3.58%   |

**Analysis:**

*   **Revenue and Profitability:** Revenue shows a generally increasing trend over the past year. Profit margins are consistently high, indicating strong pricing power and efficient operations. However, the recent drop in profit margin is a potential concern.
*   **Capital and Profitability:** Equity is growing steadily, and ROE (Return on Equity) is relatively stable.

### 7. Overall Assessment

ISRG presents a mixed picture. While the company demonstrates high historical growth, strong profitability, and a dominant position in the robotic surgery market, recent performance indicators raise concerns:

*   **Short-Term Weakness:** The stock is trading below its 20-day and 60-day moving averages, and the negative relative divergence suggests underperformance relative to the S&P 500 in the short term.
*   **Increased Volatility:** Beta has increased, and the maximum drawdown figures show substantial risk.
*   **Mixed News:** Recent news articles are a mix of concerns about the stock's decline and suggestions that it may be a buying opportunity.  Increased competition is also a factor.
*   **High Valuation:** While analysts have a positive outlook, the extremely high expected return (778.9%) should be viewed cautiously.

**Recommendation:** Given the current signals, a cautious approach is warranted. The "Hybrid Signal" suggests reducing holdings. Investors might consider waiting for more positive signals, such as a sustained move above the 20-day and 60-day moving averages, before increasing their position. Monitor news and earnings reports closely for any changes in the company's trajectory.

**Disclaimer:** This analysis is for informational purposes only and does not constitute financial advice.
